Welcome to our dedicated page for BiomX news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.
BiomX Inc. (NYSE American: PHGE) is a pioneering clinical-stage microbiome and drug discovery company based in Israel. The company specializes in the development of natural and engineered phage therapies designed to target and destroy harmful bacteria associated with chronic diseases such as inflammatory bowel disease (IBD), colorectal cancer, primary sclerosing cholangitis, and chronic pulmonary infections in cystic fibrosis (CF) patients.
Utilizing advanced computational and synthetic biology research from globally renowned institutions, including the Weizmann Institute of Science and the Massachusetts Institute of Technology (MIT), BiomX's platforms discover and validate proprietary bacterial targets. Their flagship product candidate, BX004, aims to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients. This program has shown promising clinical results, achieving positive outcomes in both safety and efficacy in Part 2 of a Phase 1b/2a trial, with results expected to be published in November 2023. BX004 has been granted Fast Track designation by the FDA.
In addition to its CF program, BiomX has expanded its pipeline through a recent merger with Adaptive Phage Therapeutics (APT), adding BX211, a personalized phage treatment for diabetic foot osteomyelitis (DFO) caused by Staphylococcus aureus. This merger has bolstered BiomX's capabilities and financial resources, enabling the company to advance its clinical pipeline effectively.
BiomX enjoys strong backing from notable investors such as OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation, Takeda Ventures, Seventure Partners, Mirae Asset Global Investments, and SBI.
For more details on BiomX's ongoing projects and latest developments, visit www.biomx.com.
BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at three virtual investor events in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investments Conference on September 13, the Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit on September 20, and the Cantor 2021 Virtual Global Healthcare Conference on September 30. Live webcasts will be available on BiomX's website, and archived materials will be accessible post-event.
BiomX (PHGE) announced a financial update for Q2 2021, highlighting a cash balance of $47.3 million, enabling operations until mid-2023. The company completed a $15 million equity raise and secured a $30 million debt agreement. Four clinical data readouts are expected by mid-2022, including Phase 2 results for acne treatment BX001 due in October. R&D expenses increased to $3.8 million, with a net loss of $7.3 million for the quarter. Upcoming milestones include trials for atopic dermatitis and cystic fibrosis therapies.
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.
BiomX (NYSE American: PHGE) has announced a registered direct offering of 3,750,000 shares and warrants for a total expected gross of $15 million. The offering price is set at $4.00 per share, with warrants exercisable for 0.75 shares at $5.00 each, expiring in five years. The proceeds will support clinical trials and general corporate purposes. The closing date is anticipated around July 28, 2021, pending customary conditions. The offering follows an effective shelf registration statement declared by the SEC in December 2020.
BiomX Inc. (PHGE) announced promising preclinical results for its phage therapy candidate, BX005, targeting Staphylococcus aureus in atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, the results indicate BX005 efficiently eradicates harmful bacteria without mutant strain emergence. CEO Jonathan Solomon emphasized its potential for safer, effective treatment options, especially for children. BiomX expects to share Phase 2 safety and efficacy results in early 2022. The conference presentations occurred on June 13 and will continue on June 17-18, 2021.
BiomX (PHGE) announced promising preclinical results for BX004, a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. Presented at the 44th European Cystic Fibrosis Conference, the data demonstrated BX004's effectiveness in reducing bacterial levels encased in biofilm, outperforming two antibiotics. Following these results, BiomX plans to advance BX004 to a Phase 1b/2a trial, with outcomes from Part 1 expected in Q1 2022. This advancement indicates the company's commitment to innovative therapies addressing chronic diseases.
BiomX (PHGE) reported Q1 2021 financial results, highlighting progress in clinical trials for its phage therapies. The company completed enrollment of 140 patients in a Phase 2 study of BX001 for acne, with results expected in Q3 and Q4. Positive safety data from BX002 for Inflammatory Bowel Disease prompted a transition to a Phase 1b/2a trial for BX003. Cash on hand was $53.6 million, supporting operations into mid-2022. R&D expenses increased to $5.8 million, and the net loss rose to $8.4 million, compared to $5.9 million in Q1 2020.
BiomX Inc. (PHGE) will host a virtual key opinion leader webinar on May 26, 2021, at 8:00 AM EDT, focusing on BX003, a phage therapy targeting Klebsiella pneumoniae for inflammatory bowel disease (IBD). Dr. Ryan Balfour Sartor, a leading expert, will discuss the efficacy of microbiome-based treatments. Following a successful Phase 1a study, BiomX aims to enter Phase 1b/2a trials evaluating BX003's safety and efficacy, with results expected by Q2 2022. Registration is available on BiomX's investor website.
BiomX Inc. (PHGE) announced a conference call on May 24, 2021, at 8:00 a.m. EDT to report its first quarter 2021 financial results and provide updates on business progress. The call will be accessible via phone and webcast on the Company’s website. BiomX is focused on developing natural and engineered phage therapies to combat specific pathogenic bacteria impacting skin health and chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at two virtual investor events in April 2021. The first is the Jefferies Microbiome-Based Therapeutics Summit on April 22, available on-demand from 8:00 AM EDT. The second is the Ladenburg Thalmann R&D Showcase on April 29 at 1:00 PM EDT, where Solomon will discuss the acne landscape and the lead product candidate, BX001, alongside Dr. Leon Kircik. Webcasts can be accessed on the company’s website.
FAQ
What is the current stock price of BiomX (PHGE)?
What is the market cap of BiomX (PHGE)?
What does BiomX Inc. specialize in?
What is BX004?
Who are BiomX's research partners?
What recent merger did BiomX complete?
Who are some of BiomX's investors?
What are some of BiomX's current projects?
Where is BiomX Inc. based?
What technological platforms does BiomX use?
When can we expect results for BX004 Phase 1b/2a trial?
How can I get more information about BiomX?
